Castle Biosciences price target raised to $40 from $34 at Lake Street
The Fly

Castle Biosciences price target raised to $40 from $34 at Lake Street

Lake Street raised the firm’s price target on Castle Biosciences (CSTL) to $40 from $34 and keeps a Buy rating on the shares. The firm, which notes that its 2025 revenue estimate is $267.3M, is raising its target after a Q3 beat to reflect better-than-expected testing volumes in several tests and multiple expansion.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App